Morgan Stanley analyst Jeffrey Hung downgraded PTC Therapeutics to Underweight from Equal Weight with an unchanged price target of $28. While the firm still find the sepiapterin profile to be “compelling” in PKU, it sees better risk-adjusted opportunities elsewhere in its pharma coverage given greater uncertainty from regulatory headwinds faced by multiple programs, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTCT:
- PTC Therapeutics initiated with an Overweight at Wells Fargo
- PTC Therapeutics initiated with bullish view at Wells Fargo
- PTC Therapeutics provides regulatory update for Translarna in Europe, the U.S.
- Biotech Alert: Searches spiking for these stocks today
- Roblox upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
